NCT06372457Active, not recruiting
COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
mavaCamten ObservationaL evIdence Global cOnsortium in HCM (COLLIGO-HCM)
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 331 (actual)
- First submitted
- 15 Apr 2024
- Start date
- 1 Dec 2023
- Primary completion date
- 29 Sept 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT06372457
What you commit to
- Study type: Observational
- Participants enrolled: 331
- From 1 Dec 2023 to the primary completion date, 29 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- HCM Sub-Cohort
- \- HCM phenocopy (athlete's heart, hypertensive heart disease, Fabry disease, Pompe disease, Danon disease, amyloidosis) observed after the first observed HCM-associated encounter in the medical record.
Who the study is looking for
- Source Cohort
- \- Have at least one recorded encounter with a Hypertrophic Cardiomyopathy (HCM) diagnosis during or after 2018 (the first is defined as the index) and aged ≥18 years on the index date.
- \- Disease-specific patient history documented in the medical record.
- HCM Sub-Cohort
- \- Participants in the source cohort with a known HCM diagnosis
- Mavacamten Sub-Cohort - Participants who have their first mavacamten prescription after the index date
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IQVIA Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
Related publications
- Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM.Circ Genom Precis Med · 2026 · PMID 41212168
This page is information, not medical advice. Discuss any trial with your doctor.